Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis.

Authors :: VAN MUIJEN, Marloes E.
THOMAS, Sarah E.
VELLINGA, Douwe
BOUWMAN, Silke
VAN DOORN, Martijn B. A.
POLITIEK, Klaziena
OTERO, Marisol E.
VAN DEN REEK, Juul M. P. A.
DE JONG, Elke M. G. J.
Source :: Acta Dermato-Venereologica; 2022, Vol. 102, p1-2, 2p
Publication Year :: 2022
Abstract: The article presents a study which aims to evaluate 1- and 2-year drug survival (DS) of guselkumab, split for discontinuation due to ineffectiveness or side-effects. It mentions that the study elucidate predictors for a shorter guselkumab DS. It informs that guselkumab has been registered as the first interleukin-23 (IL-23) inhibitor for treatment of psoriasis.

Full Text Access

Tools